Haynes and Boone Partner Joins Client Pulmatrix, Inc. at NASDAQ Bell Ringing

12/22/2015

Haynes and Boone, LLP Partner Rick Werner joined representatives of client Pulmatrix, Inc. at the NASDAQ MarketSite in Times Square to ring the Dec. 22 opening bell.

Werner took the stage with a group of Pulmatrix’s leaders, including Chief Executive Officer Robert Clarke.

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis.

Media Contacts

Nathan Koppel
Director of Media Relations
+1 512.867.8431
nathan.koppel@haynesboone.com
Linda Campbell
Communications Manager
+1 214.651.5362
linda.campbell@haynesboone.com

Related Practices

Related Industries

Email Disclaimer